Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 EV-to-FCF is 6.02 as of Jul. 21, 2026, which is 6% above its 10-year median of 5.70. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 566 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 88.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Consun Pharmaceutical Group's Enterprise Value is $970.0 Mil.
Consun Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $161.1 Mil. Therefore, Consun Pharmaceutical Group's EV-to-FCF for today is 6.02.
The historical rank and industry rank for Consun Pharmaceutical Group's EV-to-FCF or its related term are showing as below:
CPHGF'
s EV-to-FCF Range Over the Past 10 Years
Min: 0.74 Med: 5.7 Max: 35.2
Current: 6.05
During the past 13 years, the highest EV-to-FCF of Consun Pharmaceutical Group was 35.20. The lowest was 0.74. And the median was 5.70.
CPHGF's EV-to-FCF is ranked better than 88.16% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs CPHGF: 6.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Consun Pharmaceutical Group (OTCPK:CPHGF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Consun Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Consun Pharmaceutical Group's share price for today is $1.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.178.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Consun Pharmaceutical Group EV-to-FCF Related Terms
Consun Pharmaceutical Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's EV-to-FCF falls into.
Consun Pharmaceutical Group's current Enterprise Value is $970.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $161.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a EV-to-FCF of 6.02 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 5.70. Over the past decade, Consun Pharmaceutical Group's EV-to-FCF has ranged from 0.74 to 35.20. According to the industry distribution chart, Consun Pharmaceutical Group ranks #67 out of 566 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Consun Pharmaceutical Group's EV-to-FCF too high?
Consun Pharmaceutical Group's current EV-to-FCF of 6.02 is near median its 10-year median of 5.70. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 35.20. The Drug Manufacturers industry median EV-to-FCF is 20.95. Consun Pharmaceutical Group's value of 6.02 is 71.3% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #67 out of 566 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #67 out of 566 companies for EV-to-FCF. This places Consun Pharmaceutical Group in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.95. Consun Pharmaceutical Group's value of 6.02 is 71.3% below this benchmark. Historically, Consun Pharmaceutical Group's own EV-to-FCF has ranged from 0.74 to 35.20 over the past decade. While the company's 10-year median is 5.70 vs. the industry median of 20.95, Consun Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current EV-to-FCF of 6.02 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current EV-to-FCF is 6.02, which is near median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current EV-to-FCF is 6.02, which is near median its 10-year median of 5.70 and 71.3% below the Drug Manufacturers industry median of 20.95. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current EV-to-FCF is 6.02 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
EV-to-FCF: 6.02 (near median its 10-year median of 5.70)
GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
Industry Position: 71.3% below the Drug Manufacturers median (#67 of 566)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
